RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that surgeons have now performed the first 3mm micro laparoscopic robotic surgeries in the world utilizing the Senhance Surgical Robot. 3mm instruments, often referred to as micro laparoscopy, allow for surgeons to make tiny incisions that are deemed virtually scarless for patients.
The surgeries were performed at CHU Saint-Ètienne in France, and at the Policlinico A. Gemelli Foundation in Rome, Italy. Professor Celine Chauleur and Dr. Salvatore Gueli Alletti, gynecologic oncologists, and Dr. Gabriele Barabino, a general surgeon, were the first surgeons in the world to utilize micro laparoscopic instruments with an abdominal robotic surgery platform. The surgeons successfully performed multiple cases in gynecologic and general surgery such as; ovarian cystectomy, endometrial excision, total laparoscopic hysterectomy, bilateral salpingo-oophorectomy and cholecystectomy utilizing robotic microlap instruments.
“Microlaparoscopy with robotic assistance is now a reality utilizing Senhance,” said Todd M. Pope, President and CEO at TransEnterix. “The use of microlaparoscopy is a growing trend, but it can be challenging to manually control and stabilize such small instruments. We believe Senhance robotic assistance can enable surgeons to expand their use of virtually scarless surgery in more patients, and creates an additional way robotics can bring value over traditional manual approaches.”
“Patients are consistently interested in the least invasive approach possible,” said Dr. Barabino. “Utilizing 3mm microlap instruments with the Senhance Surgical Robot creates a virtually scarless approach with the precision of robotics to control such small instruments with delicate haptic force feedback.”
About TransEnterix
TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark, and is currently under FDA review for clearance in the United States. For more information, visit the TransEnterix website at www.transenterix.com.
Read More at the Source: TransEnterix Announces Enhanced Capability to Perform Micro Incision Robotic Surgery | Business Wire